drugset
drugset / Trial / NCT05661643

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

NCT05661643 ↗

Phase 2 Recruiting 29 enrolled Asan Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.

Timeline

Start
2023-06-28
Primary completion
2026-12-01
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 200 mg/m2 Oral

Indications

gastrointestinal stromal tumor